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 vi   
Summary 
This report presents information on expenditure for diabetes in Australia in 2008–09, as well 
as information on how this expenditure has changed in the last decade and how it is 
expected to grow in the future. Expenditure is presented by sex, age and diabetes type for 
2000–01 to 2008–09. The report also looks at how per service expenditure differs from per 
capita expenditure across age groups and by diabetes type. 
The report is based primarily on recurrent diabetes expenditure for the health-care sectors 
hospital admitted patient services, out-of-hospital medical expenses, and blood glucose 
lowering medications. There is also a section on additional expenditure that mainly reports 
on funding of government programs to help manage diabetes in the community and funding 
for research into the disease. 
It should be noted that not all health-care expenditure can be allocated to a specific disease 
because expenditure in areas such as capital works or administration is common to all 
diseases. For this reason, the estimates in the report are based on about 70% of total health-
care expenditure. There are other limitations to the data and these are explained in the 
Methods section of the report. 
Main findings  
• In 2008–09, estimated expenditure for diabetes, allocated by health-care sector, totalled 
$1,507 million—2.3% of all allocated health-care expenditure in Australia. An additional 
$153 million was spent on government programs and subsidies, research and gestational 
diabetes programs. 
• Diabetes expenditure increased by 86% between 2000–01 and 2008–09 while expenditure 
for all diseases increased by 60% in the same period. 
• Type 2 diabetes accounted for at least 60% of diabetes expenditure in 2008–09. 
• In 2008–09, diabetes expenditure for hospital admitted patient services was 
conservatively estimated at $647 million, for out-of-hospital medical expenses it was 
$362 million and for blood glucose lowering medications it was $498 million. 
• After adjusting for inflation, the biggest increase in diabetes health-care expenditure 
from 2000–01 to 2008–09 was for hospital admitted patient services—expenditure more 
than doubled, from $300 million to $647 million. 
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Introduction 
Diabetes is a significant health problem in Australia. It was the main cause of 4,170 deaths in 
2009 (3% of all deaths) and an associated cause in many more, contributing to 1 out of every 
10 deaths (AIHW 2012a). Between 1997 and 2007, diabetes was a particularly common 
contributory cause for deaths involving chronic and unspecified kidney failure (20%), 
coronary heart disease (16%) and asthma (16%) (AIHW 2012b). The most recent estimate of 
the number of Australians with diabetes is around 986,900, or 4.5% of the Australian 
population (ABS 2012), but the true burden of disease is thought to be much greater because 
many more of those with diabetes may be unaware that they have the condition. For 
example, the 2009–10 Victorian Health Monitor suggests that for every three diagnosed cases 
of diabetes in Victoria, there is one undiagnosed case (Victorian Department of Health 2012). 
Diabetes generates a considerable economic burden, both at an individual level and to the 
Australian health-care system. 
The report updates expenditure information in the Australian Institute of Health and 
Welfare (AIHW) publication Diabetes Australian facts 2008 (AIHW 2008). Most data are drawn 
from the AIHW Disease Expenditure Database and presented by age, sex and type of 
diabetes for 2008–09. Changes in expenditure for 2000–01 to 2008–09 are also examined and 
additional information on diabetes treatment products, gestational diabetes programs and 
government-funded projects and research is included. 
Between 2000–01 and 2008–09, allocated health-care expenditure for diabetes increased from 
$811 million to $1,507 million, an increase of 86%. For all diseases, the comparable increase in 
expenditure was 60%. Diabetes expenditure increased from 2.0% to 2.3% of expenditure for 
all diseases over this period. 
The increasing prevalence of diabetes in Australia is influenced by a number of factors, 
including an ageing population (noting that diabetes prevalence increases with age), 
increases in the number of new cases (incidence) of diabetes (which is being driven primarily 
by increases in obesity), and decreasing mortality rates among those with diabetes. 
Immigration from countries with higher diabetes prevalence rates may also have served to 
increase diabetes prevalence in Australia (Magliano et al. 2009). 
It is estimated that as a result of ageing alone, the number of people with Type 2 diabetes 
will double between 2000 and 2051 and health-care costs for diabetes will increase 2.5 times. 
In addition, if obesity and inactivity prevalence rates continue to rise, the financial burden of 
treating Type 2 diabetes could quadruple by 2051 (Davis et al. 2006). 
 
.  
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Box 1: Diabetes in Australia 
Based on self-reported data from the Australian Bureau of Statistics’ 2011–12 Australian 
Health Survey, an estimated 986,900 Australians had been diagnosed with diabetes 
(excluding gestational diabetes) at some time in their lives. This represented 4.5% of the 
Australian population. Of those diagnosed, 54% were male and 46% were female. 
Type 1 diabetes 
• An estimated 113,400 people had Type 1 diabetes (12% of people with diabetes). 
• Of those with Type 1 diabetes, around 68,600 (60%) were male and 44,800 (40%) were 
 female. 
Type 2 diabetes 
• An estimated 842,300 people had Type 2 diabetes (85% of people with diabetes). 
• Of those with Type 2 diabetes, around 448,200 (53%) were male and 394,100 (47%) 
 were female. 
Age distribution 
The age distribution of people with Type 1 and Type 2 diabetes was derived from the 
National Diabetes Services Scheme (NDSS) as at 30 June 2009. 
• The number of people with Type 1 diabetes increased steadily with age, from 16,803 in 
 the 0 to 24 year age group to 43,195 of those aged 65 and over. About 50% of those with 
 Type 1 diabetes were aged 55 and over.  
• The number of people with Type 2 diabetes also increased with age, from 1,974 of 
 those aged 0 to 24 to 373,532 of those aged 65 and over. About 77% of those with Type 
 2 diabetes were aged 55 and over. 
 
 
Source: AIHW analysis of the National Diabetes Services Scheme database. 
Figure 1: Number of people with diabetes, by diabetes type and age group, 30 June 2009 
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Methods 
The expenditure estimates reported here provide a broad picture of the use of health system 
resources classified by disease. The method for estimating disease expenditure is generally a 
‘top–down’ approach where total expenditure across the health system is estimated and then 
allocated to the relevant conditions. Although this method yields consistency, good coverage 
and totals that add up to known expenditures, it is not as sensitive or accurate for any 
specific disease as a detailed ‘bottom–up’ analysis of actual costs incurred by patients with 
that disease. In most cases, however, a bottom-up analysis is not possible due to a lack of 
data. 
The predominant source of information for this report is the AIHW Disease Expenditure 
Database. It provides a broad picture of the use of health system resources classified by 
disease group, and is a reference source for planners and researchers interested in costs and 
use patterns for particular disease groups. These results are also useful for comparing 
expenditure for different diseases and for ranking diseases by levels of expenditure. 
Estimates in the Disease Expenditure Database are derived by combining information from 
the National Hospital Morbidity Database (NHMD), the National Public Hospitals 
Establishments Database (NPHED), the Health Expenditure Database, the National Hospital 
Cost Data Collection (NHCDC) and the Bettering the Evaluation and Care of Health 
(BEACH) survey. The AIHW is continually seeking to improve the methods used to produce 
these estimates. As a consequence, disease expenditure estimates are subject to revision and 
the most recently published results may not be comparable with previously published data. 
The Disease Expenditure Database contains estimates of expenditure by disease category, 
age group and sex for admitted patient hospital services, out-of-hospital medical services, 
prescription pharmaceuticals, optometrical and dental services, community mental health 
services and public health cancer screening. (Note that throughout this report prescription 
pharmaceuticals are referred to as blood glucose lowering medications. This change was 
made to make it clear that only expenditure for medications to treat diabetes has been 
included and that expenditure for other medications that a person with diabetes may be 
taking—to treat a co-existing condition—is not included in this report.) 
A data quality statement for the Disease Expenditure Database is in Appendix A. This 
provides information on a range of aspects of the quality of the data being reported by the 
AIHW and is included to assist readers in understanding the limitations of the data and in 
making informed judgments about their use of the data. 
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that could not be allocated by disease includes: capital expenditure, non-
admitted patient hospital services, over-the-counter drugs, other health practitioner services 
(except optometry), community health services expenditure (except community mental 
health), expenditure on public health programs (except cancer screening programs), health 
administration, health aids and appliances, and patient transport (ambulance). As a result, 
the estimates in this report are conservative as they are based on the approximately 70% of 
total direct health expenditure that can be allocated by disease (AIHW 2010). Diabetes 
health-care expenditure for high-level residential aged care is not included in this report 
because it is categorised as a welfare sector rather than a health-care sector. 
Readers need to bear in mind that cost-of–illness data only provide estimates of the impact a 
disease has on health system expenditures. The estimates of the cost of treating and/or 
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preventing a disease cannot be used to indicate the loss of health due to that disease, or to 
understand other effects, such as loss of productivity.  
Care should be taken not to interpret expenditure associated with disease treatment as 
simply an estimate of the savings that would result from prevention of disease. Conversion 
of the opportunity cost—or the benefits forgone—of resources being devoted to disease 
treatment into expenditure savings involves a number of additional considerations. See, for 
example, AIHW: Mathers & Penm 1998. 
Hospital admitted patients 
Expenditure for hospital admitted patient services is based on hospital separations (episodes 
of care) and is allocated to the International Classification of Diseases, tenth revision (ICD-
10) code recorded as the principal diagnosis for each separation. No expenditure is allocated 
for additional diagnoses. In 2009–10, diabetes was a principal diagnosis in 96,166 
hospitalisations and an additional diagnosis in a further 248,514 (AIHW 2012a), which 
suggests that expenditure for hospital admitted patient services is likely to be a conservative 
estimate of the true level of diabetes-related expenditure.  
In this report, expenditure was assigned to diabetes when the principal diagnosis was either 
ICD-10 AM code E10 (Type 1 diabetes mellitus), E11 (Type 2 diabetes mellitus), E13 (Other 
specified diabetes mellitus) or E14 (Unspecified diabetes mellitus). Diabetic complications 
that are included in the ICD-10 as subtypes of ICD-10 codes E10–E14 were included in this 
assessment under the appropriate diagnostic code (Table 1). Unless specifically assigned to 
diabetes as a principal diagnosis, expenditure on complications of diabetes, such as heart or 
kidney disease, is allocated to those diseases and is not included in diabetes expenditure. If, 
for example, the principal diagnosis for a hospital separation was cardiovascular disease 
(CVD) with an additional diagnosis of diabetes, then all the expenditure associated with that 
separation would be counted as expenditure for CVD and the expenditure associated with 
treating the diabetes in that patient while they were in hospital would not be captured. By 
way of illustration, in 2008–09, about 23% of hospitalisations with a principal diagnosis of 
chronic kidney disease had an additional diagnosis of diabetes.  
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Table 1: Principal diagnosis ICD-10 AM codes used for hospital admitted patient services 
ICD-10 AM code Description 
E10 Type 1 diabetes mellitus 
E11 Type 2 diabetes mellitus 
E13 Other specified diabetes mellitus 
E14 Unspecified diabetes mellitus 
Subtypes of ICD-10 codes E10, E11, E13 and E14   
E’x’.0 Diabetes mellitus with hyperosmolarity 
E’x’.1 Diabetes mellitus with acidosis 
E’x’.2 Diabetes mellitus with kidney complication 
E’x’.3 Diabetes mellitus with ophthalmic complication 
E’x’.4 Diabetes mellitus with neurological complication 
E’x’.5 Diabetes mellitus with circulatory complication 
E’x’.6 Diabetes mellitus with others specified complication 
E’x’.7 Diabetes mellitus with multiple complications 
Note: ‘x’ can equal 10, 11, 13 or 14. For example, E10.0 refers to Type 1 diabetes mellitus with hyperosmolarity. 
Cases where the principal diagnosis was Impaired glucose regulation (IGR) (ICD-10 AM 
code E09) or Diabetes mellitus in pregnancy, childbirth, and the puerperium (ICD-10 AM 
code O24), were not included in the totals for diabetes. IGR was omitted because, although it 
is a risk factor for diabetes, it is not considered to be a condition in its own right and ICD-10 
code O24, which includes gestational diabetes mellitus (GDM) and pre-existing diabetes 
mellitus in pregnancy, is an obstetrics code. In this case, all expenditure associated with O24 
is recorded as obstetrics expenditure rather than diabetes expenditure. See ICD-10 AM 
coding for further information (WHO 2010). In 2008–09, there were 48,000 hospital 
separations with either a principal or additional diagnosis of gestational diabetes. GDM-
related expenditure is considered separately in the ‘Additional expenditure not allocated by 
health-care sector’ section of this report. 
Out-of-hospital medical services and blood glucose 
lowering medications 
Diabetes expenditure estimates for out-of-hospital medical services and blood glucose 
lowering medications presented in this report are derived using the BEACH survey in 
conjunction with data from a number of other sources including the Medicare Benefits 
Schedule (MBS), Pharmaceutical Benefits Scheme, Repatriation Pharmaceutical Benefits 
Scheme, and script volumes for private and under co-payment drugs. The BEACH data were 
collected by the Family Medicine Research Centre of the University of Sydney under a 
previous collaboration with the AIHW. 
For out-of-hospital medical services, the BEACH survey data were aggregated over 3 years 
to estimate the proportion of general practitioner (GP) encounters in which diabetes was a 
‘problem managed’. This proportion was then applied to the MBS data for the reference year. 
Based on this method, expenditure can be allocated for GP visits and referrals to medical 
specialists, pathology and imaging. With the exception of diabetes educators, expenditure for 
allied health services has not been allocated for diabetes. An independent study assessing the 
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burden of Type 1 diabetes in Australia estimates expenditure for allied health professionals 
at 4.8% of direct health-care costs (Colagiuri et al. 2009). 
For blood glucose lowering medications, the BEACH survey data were aggregated over 
3 years to allocate expenditure on prescription drugs to each disease group based on the 
problems managed in the GP encounter that related to the prescribing of a particular drug. 
The Anatomical Therapeutic Chemical Classification System codes were mapped to codes for 
prescription drugs used in the BEACH survey. Time series comparisons for both out-of-
hospital medical services and blood glucose lowering medications should be treated with 
caution because GP prescription and referral patterns may have varied over time. 
Only drugs prescribed specifically for diabetes (namely insulin, oral hypoglycaemic agents 
and some newer blood glucose lowering medications) are included in the expenditure in this 
report. The cost of medications prescribed for the management of conditions associated with 
diabetes, such as high blood pressure, are not included. The DiabCo$t Australia project 
estimates that for patients with Type 2 diabetes, insulin and oral hypoglycaemic agents 
accounted for only 21% of medication costs, with the majority coming from non-diabetes 
medications such as lipid lowering and blood pressure lowering agents (Colagiuri et al. 
2003). In a 2002 study, expenditure for non-blood glucose lowering medications were 
estimated to be 26% of total direct health-care costs incurred by Australians with Type 2 
diabetes (Davis et al. 2005).  
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Diabetes expenditure 
Expenditure allocated by health-care sector 
From the data available, in 2008–09, diabetes was the 14th most expensive disease in 
Australia, accounting for 2.3% of total recurrent health-care expenditure for all diseases; that 
is, $1,507 million of the $65,129 million spent for all diseases (Table 2).  
Hospital admitted patient services 
The health-care sector with the highest level of diabetes-related expenditure in 2008–09 was 
hospital admitted patient services ($647 million), accounting for nearly 43% of total health-
care expenditure for diabetes. More than 85,000 separations were provided under hospital 
admitted patient services, at an average expenditure of just under $7,600 each. 
Blood glucose lowering medications 
Expenditure for blood glucose lowering medications was next highest at $498 million, 
accounting for about one-third of total health-care expenditure for diabetes. Nearly  
10.6 million prescriptions were dispensed, at an average expenditure of $47 each. 
Out-of-hospital medical expenses 
Out-of-hospital medical expenses accounted for a further $362 million, under which nearly 
8.7 million services were provided, at an average expenditure of $42 per service. 
Expenditure for diabetes is distributed differently to that for all diseases. For example, nearly 
43% of total diabetes health-care expenditure was allocated to hospital admitted patient 
services, proportionally much less than the 59% of all diseases expenditure allocated to this 
health-care sector. Conversely, 33% of diabetes expenditure was allocated to blood glucose 
lowering medications compared with the 16% for all diseases. About the same proportion of 
total expenditure (24%) was allocated for out-of-hospital medical expenses for both diabetes 
and all diseases (Table 2). 
Table 2: Diabetes and all disease expenditure by health-care sector, Australia, 2008–09 
 Diabetes  All diseases 
Health-care sector $ (million) Per cent  $ (million) Per cent 
Hospital admitted patient services(a)(b) 647 42.9  38,675 59.4 
Out-of-hospital medical expenses 362 24.0  15,871 24.4 
Blood glucose lowering medications 498 33.1  10,583 16.2 
Total allocated expenditure 1,507 100.0  65,129 100.0 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
Source: Disease Expenditure Database, AIHW. 
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Additional expenditure not allocated by health-care 
sector 
There is additional health-care expenditure associated with the management of diabetes 
apart from that classified by disease and health-care sector. 
In 2008–09, the Australian Government spent more than $127 million subsidising blood 
glucose test strips, syringes, needles and items for use with insulin pumps, supplied through 
the National Diabetes Services Scheme; $2.8 million on the National Diabetes Strategy; more 
than $4.3 million in Council of Australian Governments (COAG) diabetes grants; nearly 
$3 million on both the Diabetes Pilot Program and on diabetes community educators; close to 
$10 million on support for diabetes research, and nearly $500,000 in payments to the Juvenile 
Diabetes Research Foundation (JDRF) to support the purchase of insulin pumps by low-
income earners. (See Glossary for further information about these programs.) In addition, 
more than $2 million was spent on out-of-hospital medical expenses and blood glucose 
lowering medications for gestational diabetes. Together with health sector expenditure 
allocated to diabetes, these additional expenses brought the total estimated direct 
expenditure for diabetes in 2008–09 to $1,660 million (Table 3). 
Table 3: Diabetes expenditure, Australia, 2008–09 
Area of expenditure $ (million) 
Health sector(a)  1,507.3 
Health sector—gestational diabetes only(b) 2.0 
Blood glucose test strips, syringes, needles and items for insulin pumps 127.4 
National Diabetes Strategy 2.8 
COAG diabetes grants 4.3 
Diabetes Pilot Program 2.9 
Support for diabetes research 9.8 
Diabetes community educators 2.9 
Insulin pumps (JDRF) 0.5 
Total for 2008–09(c) 1,659.9 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure on out-of-hospital medical expenses and blood glucose lowering medications only.  
(c)  Values may not sum to the total due to rounding. 
Note: Expenditure for gestational diabetes does not include hospital-admitted patient expenditure. This expenditure is attributable to  
ICD-10 code O24 (Diabetes mellitus in pregnancy).   
Source: Disease Expenditure Database, AIHW. 
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Expenditure by sex 
In 2008–09, overall expenditure for the treatment of diabetes was greater for males 
($845 million or 56%) than for females ($662 million or 44%). This is consistent with the fact 
that there are more males than females with diabetes (Box 1). Overall expenditure was also 
higher for males within each health-care sector (Figure 2). The sector where the difference 
was most marked was hospital admitted patient services, where 58% of diabetes expenditure 
was for males and 42% for females. 
Per separation expenditure for hospital admitted patient services was also higher for males 
($8,197) than for females ($6,828). However, for the health-care sectors out-of-hospital 
medical expenses and blood glucose lowering medications, both per service and per 
prescription expenditure, at between $41 and $48, were similar for males and females (See 
Table B1). 
  
Note: Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
Source: Disease Expenditure Database, AIHW. 
Figure 2: Diabetes expenditure by health-care sector and sex, Australia, 2008–09 
Expenditure by age 
In 2008–09, expenditure for diabetes across all health-care sectors varied considerably 
between age groups. It was lowest ($53 million) for people aged 0 to 24 and increased with 
age from $132 million for those aged 25–44, to $563 million for those aged 45–64 and 
$683 million for those aged 65 to 84. Expenditure then fell to $77 million for people aged 85 
and over (Table B6). This pattern is consistent with the age distribution of people with 
diabetes (Box 1). Hospital admitted patient services was the health-care sector with the 
highest level of expenditure for each age group, except for those aged 45 to 64. In this age 
group, more was spent on blood glucose lowering medications ($211 million) than on 
hospital admitted patient services ($197 million) (Figure 3). Per service expenditure varied by 
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age for the health-care sectors hospital admitted patient services and blood glucose lowering 
medications, but not significantly for out-of-hospital medical expenses. 
  
Note: Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
Source: Disease Expenditure Database, AIHW. 
Figure 3: Diabetes expenditure by age and health-care sector, Australia, 2008–09 
Hospital admitted patient services 
For hospital admitted patient services, expenditure was lowest at $4,516 per separation for 
those aged 0–24, increased to $6,946 for those aged 25–44 and peaked at $9,343 for those aged 
45–64. It then fell to $7,008 for 65 to 84 year olds before increasing again to $8,501 for those 
aged 85 and over. An overall increase of 88% between the youngest and oldest age groups 
was recorded. 
Blood glucose lowering medications 
In contrast, for blood glucose lowering medications, prescription costs decreased with age 
from $118 per prescription for those aged 0–24 to $83 for 25–44 year olds, and then to $49 or 
less for other ages—an overall decrease of 68% between the youngest and oldest age groups. 
Per capita expenditure showed a similar pattern for blood glucose lowering medications: it 
was highest for the 0–24 age group ($1,011 per person), decreased to between $550 and $625 
per person for those aged 25–84 and was lowest for those aged 85 and over ($268 per 
person), an overall decrease of 73%. 
Although good quality data describing the types of medicines prescribed for Type 1 and 
Type 2 diabetes are not available, the overall decrease in per capita expenditure for blood 
glucose lowering medications with increasing age may be the result of the changing 
distribution of diabetes types with age. For example, in the 0–24 age group, 93% of all those 
with diabetes have Type 1 diabetes while for those aged 25–34 it comprises 54% of the total, 
after which Type 2 diabetes becomes the predominant form (Box 1). The higher levels of 
expenditure for younger age groups may reflect the fact that in all cases of Type 1 diabetes, 
insulin, which is relatively more expensive than most other oral blood glucose lowering 
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agents, is required daily for survival. On the other hand, pharmacological management of 
Type 2 diabetes may include insulin and/or oral medication. Recent studies found that of 
those with Type 2 diabetes, only 19–22.5% relied on insulin (Davis et al. 2012; Diabetes 
Australia 2012), with many patients controlling their diabetes using markedly cheaper oral 
blood glucose lowering drugs, such as metformin hydrochloride. 
Out-of-hospital medical expenses 
Per service expenditure for out-of-hospital medical expenses also decreased with age, falling 
from $56 per service for those aged 0–24 to $49 for the 25–44 age group, and then to $40 for 
those aged 85 and over, representing an overall fall of 29% (Table 4). Per capita expenditure, 
however, showed the opposite overall trend. At $191 per person, it was lowest for those aged 
0–24, before rising to its peak at $459 for those aged 65–84 and then declining to $207 per 
person for those 85 and over. 
Table 4: Average expenditure per encounter with the health system, by health-care sector by age, 
Australia, 2008–09 
 
Health-care sector 
0 to 24 
years 
25 to 44 
years 
45 to 64 
years 
65 to 84 
years 
85+ 
years 
All 
ages 
   $    
Hospital admitted patient 
services(a)(b) 4,516 7,850 9,343 7,008 8,501 7,567 
Out-of-hospital medical expenses 56 49 43 39 40 42 
Blood glucose lowering medications 118 83 48 40 38 47 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
Source: Disease Expenditure Database, AIHW. 
Changes in health-care expenditure over time 
After adjusting for inflation within the health system, total expenditure for diabetes 
increased from $811 million in 2000–01 to $1,507 million in 2008–09, representing an average 
growth of about 10% per year. Total expenditure for diabetes increased from 2.0% to 2.3% of 
total allocated expenditure for all diseases for 2000–01 to 2008–09 (Table B3). 
Hospital admitted patient services 
The largest expenditure increase, by health-care sector, was for hospital admitted patient 
services, where expenditure increased by 116%, from $300 million to $647 million, between 
2000–01 and 2008–09 (Figure 4). Expenditure for hospital admitted patient services as a 
proportion of total expenditure for diabetes increased from 37% to 43% over this period. 
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Note: Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
Sources: Disease Expenditure Database, AIHW; National Diabetes Services Scheme database. 
Figure 4: Diabetes expenditure, by health-care sector, constant prices, Australia, 2000–01, 2004–05, 
2008–09 
Per separation expenditure for hospital admitted patient services was calculated using the 
number of hospital separations with a principal diagnosis of diabetes as the denominator. 
Between 2000–01 and 2004–05, per separation expenditure for this sector remained steady at 
$6,452 and $6,341 respectively, before increasing by 19% to $7,567 in 2008–09 (Figure 5). 
Out-of-hospital medical expenses and blood glucose lowering 
medications 
Between 2000–01 and 2008–09, the amount spent on out-of-hospital expenses increased 35%, 
from $269 million to $362 million. Expenditure for blood glucose lowering medications rose 
106%, from $242 million to $498 million. As a proportion of total expenditure for diabetes, 
out-of-hospital expenses fell from 33% to 24%, while expenditure for blood glucose lowering 
medications increased from 30% to 33% over this period. 
The proportion of GP encounters at which diabetes was managed also increased over this 
period, from 2.8 per 100 encounters in 2000–01 to 4.1 per 100 in 2008–09 (Britt et al. 2009). 
This may partially explain the increase in the amount of expenditure allocated for these two 
health-care sectors over this period. Expenditure trends for out-of-hospital expenses and 
blood glucose lowering medications should be treated with caution, however, because they 
are derived from the BEACH survey of general practitioners and prescribing and referral 
patterns may have varied over time.  
Per capita expenditure 
Despite diabetes expenditure increasing for each health-care sector between 2000–01 and 
2008–09, per capita expenditure for out-of-hospital medical expenses and blood glucose 
lowering medications decreased by 40% and 9% respectively (Figure 6). Per capita 
expenditure for out-of-hospital services fell from $704 to $420 in that period and from $633 to 
$577 for blood glucose lowering medications, including a sharp decrease of 28% for 
medications between 2000–01 and 2004–05. The denominator used to calculate per capita 
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expenditure for out-of-hospital medical expenses and blood glucose lowering medications is 
the total number of registrants in the NDSS. From 2000–01 to 2008–09, the number of 
registrants increased from 382,185 in 2001 to 862,743 in 2009. This represents an increase of 
126%—which is greater than the rate of increase in spending for either health-care sector, 
resulting in a decline in per capita expenditure. The substantial increase in the number of 
NDSS registrants may reflect both an increased awareness of diabetes in the community and 
better ascertainment of the disease. 
 
  
Note: Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
Sources: Disease Expenditure Database, AIHW; National Diabetes Services Scheme database. 
Figure 5: Per separation diabetes expenditure, for hospital admitted patient services, constant 
prices, Australia, 2000–01, 2004–05, 2008–09 
 
 
Sources: Disease Expenditure Database, AIHW; National Diabetes Services Scheme database. 
Figure 6: Per capita diabetes expenditure, by health-care sector, constant prices, Australia, 2000–01, 
2004–05, 2008–09 
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Expenditure by diabetes type 
In 2008–09, Type 2 diabetes accounted for more than 60% of allocated diabetes health-care 
expenditure and Type 1 diabetes for a little more than 14%. A further 25% was for Other 
forms of diabetes /Unspecified diabetes type. It is important to note that the type of diabetes 
was not specified in a large proportion of records for out-of-hospital medical expenses and 
blood glucose lowering medications and, while it is probable that a majority of the 
unspecified records would be for Type 2 diabetes, it is not possible to be certain. Further, the 
latest prevalence data for diabetes in Australia indicate that about 85% of people with 
diabetes have Type 2 (Box 1), supporting the assertion that a significant proportion of the 
expenditure allocated for Other or Unspecified diabetes would have been allocated as Type 2 
expenditure, had all cases been correctly identified by diabetes type. Therefore, it is likely 
that Type 2 diabetes accounts for more than the 60% of expenditure mentioned above. 
Hospital admitted patient services 
More was spent on hospital admitted patient services for people with Type 2 diabetes 
($544 million) than for any other health-care sector for either Type 1 or Type 2 diabetes 
(Figure 7). Of total diabetes expenditure for hospital admitted patient services, just over 84% 
was for Type 2 diabetes, about 15% for Type 1 diabetes and just 1% for Other 
diabetes/Unspecified diabetes type. 
 
Notes 
1.  Other diabetes includes ICD-10 category E13 only (Other specified diabetes) and Unspecified diabetes includes category E14 only. 
2.  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
Source: Disease Expenditure Database, AIHW. 
Figure 7: Diabetes expenditure by diabetes type and health-care sector, Australia, 2008–09  
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Out-of-hospital medical expenses and blood glucose lowering 
medications 
The distribution of expenditure by diabetes type is quite different for out-of-hospital medical 
expenses and blood glucose lowering medications than for hospital admitted patient 
services. For these two health-care sectors, comparatively smaller proportions of expenditure 
were allocated for Type 2 diabetes (48% and 40% respectively compared with 84%) and 
much larger proportions (45% and 41% compared with 1%) for Other diabetes/Unspecified 
diabetes type (Table 5). As indicated above, expenditure allocated to Other 
diabetes/Unspecified diabetes type is probably influenced by a lack of specification in 
medical records and it is likely that expenditure for both out-of-hospital medical expenses 
and blood glucose lowering medications is an underestimate for Type 2 diabetes and an 
overestimate for Other/Unspecified diabetes (Table 5). 
Table 5: Expenditure by health-care sector and diabetes type, Australia, 2008–09 
 Health-care sector Type 1 diabetes Type 2 diabetes Other/Unspecified diabetes 
 Per cent 
Hospital admitted patient 
services(a)(b) 14.8 84.1 1.1 
Out-of-hospital medical expenses 6.3 48.4 45.4 
Blood glucose lowering medications 19.2 39.8 41.0 
Total allocated expenditure(c) 14.2 60.9 24.9 
(a)  Other diabetes includes ICD-10 category E13 only (Other specified diabetes) and Unspecified diabetes includes category E14 only. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
(c)  Values may not sum to the total due to rounding. 
Sources: Disease Expenditure Database, AIHW; National Diabetes Services Scheme database. 
For hospital admitted patient services, the average expenditure per separation was 
noticeably lower for Type 1 diabetes ($5,851) than for Type 2 diabetes ($7,972) or Other 
diabetes/Unspecified diabetes type ($8,024). Conversely, for blood glucose lowering 
medications per prescription expenditure was significantly higher for Type 1 diabetes ($165 
per script) than for Type 2 diabetes ($36) or Other diabetes/Unspecified diabetes type ($46). 
Again, this may reflect the greater cost of insulin compared with most other blood glucose 
lowering medications. Similarly, for out-of-hospital expenses, per service expenditure was 
higher for Type 1 diabetes ($54) than for Type 2 ($42) or Other diabetes/Unspecified diabetes 
type ($40).  
 16 Diabetes expenditure in Australia 2008–09 
Discussion 
The number of people in Australia with diabetes has increased by an estimated 88,100 in the 
last 5 years, from 898,800 in 2004–05 to 986,900 in 2011–12. Further, a recent study in Victoria 
suggests that these figures underestimate the size of the problem, with one case of diabetes 
remaining undiagnosed for every three cases diagnosed (Victorian Department of Health 
2012).  
Diabetes prevalence has been trending upwards, both in Australia and globally since at least 
1980 (Danaei et al. 2011) and projections for the future burden of diabetes, in particular 
Type 2 diabetes, suggest that by 2030 diabetes will affect 8.4% of the Australian population 
aged 20 to 79—up from 7.2% in 2010 (Shaw et al. 2009). Another study suggests that by 2023 
diabetes will be the leading cause of disease burden among males, and second only to 
anxiety and depression among females (Begg et al. 2007).  
The increasing prevalence of diabetes in Australia is being driven by an ageing population 
(among which diabetes prevalence is highest), increases in the number of new cases 
(incidence) of diabetes (which is being driven primarily by increases in obesity) and 
decreasing mortality rates among those with diabetes. Immigration from countries with 
higher diabetes prevalence rates may also have increased diabetes prevalence in Australia 
(Magliano et al. 2009). 
The number of people registering with the National Diabetes Services Scheme has increased 
considerably since 2000–01, suggesting both an increasing awareness of the disease in the 
Australian population and its more accurate ascertainment. The increase in the numbers of 
registrants makes it difficult to determine whether the decreases in per capita expenditure 
noted for out-of-hospital expenses and blood glucose lowering medications are true 
decreases or the result of the number of registrants increasing at a greater rate. 
It is important to note that the estimates in this report are believed to underestimate the true 
levels of expenditure for the treatment of diabetes in Australia. The limitations of the data 
and the methods used are important and have been explained in detail in the Methods 
section of the report.  
Despite these limitations, which prevent a complete picture of diabetes health-care 
expenditure from being obtained, the latest information is used to show how the 70% of 
health-care expenditure for diabetes that can be allocated by disease is distributed by age, 
sex and diabetes type and how overall and per service diabetes expenditure has changed in 
the last decade.  
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Appendix A Data quality statement 
Disease expenditure database 2008–09 
Summary of key data quality issues 
• The Disease Expenditure Database contains estimates of expenditure by disease 
category, age group and sex for each of the following areas of expenditure: admitted 
patient hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services and public health 
cancer screening.  
• Estimates are derived from combining information from the National Hospital 
Morbidity Database (NHMD), the National Public Hospitals Establishments Database 
(NPHED), the Health expenditure database, the National Hospital Cost Data Collection 
(NHCDC) and the Bettering the Evaluation and Care of Health (BEACH) survey.  
• The database contains a conservative estimate of total expenditure and equates to 
around 70% of total recurrent health expenditure.  
Description 
The Disease Expenditure Database contains estimates of expenditure by disease category, 
age group and sex for admitted patient hospital services, out-of-hospital medical services, 
prescription pharmaceuticals, optometrical and dental services, community mental health 
services and public health cancer screening. Definitions for admitted patient hospital 
services, out of-hospital medical services and prescription pharmaceuticals are as follows: 
Admitted patient hospital costs refer to the cost of services for admitted patients in both 
public and private acute hospitals and psychiatric hospitals, as well as expenditure on 
medical services provided to private admitted patients in hospitals. 
Out-of-hospital medical expenses refer to the cost for services provided by, or on behalf of, 
registered medical practitioners that are funded by the Medicare Benefits Schedule (MBS), 
Department of Veterans’ Affairs, compulsory motor vehicle third-party insurance, workers 
compensation insurance, private health insurance funds, Australian Government premium 
rebates allocated to medical services, MBS co-payments and other out-of-pocket payments. 
They also include non-MBS medical services, such as the provision of vaccines for overseas 
travel, as well as some expenditure by the Australian Government under funding 
arrangements that are alternatives to the fees for service. They exclude medical services 
provided to public admitted patients in public hospitals and medical services provided to 
public patients at outpatient clinics in public hospitals. Also excluded are the costs for 
medical services provided to private admitted patients in hospitals, which are counted as 
part of admitted patient costs.  
Prescription pharmaceuticals refer to the cost of pharmaceuticals that are listed in the 
schedule of the pharmaceuticals under the Pharmaceutical Benefits Scheme (PBS) and the 
Repatriation Pharmaceutical Benefits Scheme (RPBS) for which pharmaceutical benefits have 
been paid or are payable. Also included are the costs for under copayment prescriptions and 
private prescriptions. Under copayment prescriptions are those pharmaceuticals listed in the 
PBS or RPBS, the total costs of which are equal to or less than the statutory patient 
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contribution for the class of patient concerned, while private prescriptions are those 
pharmaceuticals dispensed through private prescriptions that do not fulfil the criteria for 
payment or benefit under the PBS or RPBS. 
Estimates are derived from combining information from the National Hospital Morbidity 
Database (NHMD), the National Public Hospitals Establishments Database (NPHED), the 
National Hospital Cost Data Collection (NHCDC) and the Health expenditure database.  
Proportions derived from the Bettering the Evaluation and Care of Health (BEACH) survey 
relating to 2007 to 2009 are also used in compiling the estimates for out-of-hospital medical 
services and prescription pharmaceuticals. The BEACH data were collected by the Family 
Medicine Research Centre of the University of Sydney in collaboration with the Australian 
Institute of Health and Welfare.  
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that was not able to be allocated by disease includes: capital expenditure, 
non-admitted patient hospital services, over-the-counter drugs, other health practitioner 
services (except optometry), community health services expenditure (except community 
mental health), expenditure on public health programs (except cancer screening programs), 
health administration, health aids and appliances, and patient transport (ambulance). 
Institutional environment 
The Australian Institute of Health and Welfare (AIHW) is a major national agency set up by 
the Australian Government under the Australian Institute of Health and Welfare Act 1987 to 
provide reliable, regular and relevant information and statistics on Australia’s health and 
welfare. It is an independent statutory authority established in 1987, governed by a 
management board, and accountable to the Australian Parliament through the Health and 
Ageing portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the AIHW’s main functions is to work with the states and territories to improve the 
quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these datasets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwlth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information, see the AIHW website <http://www.aihw.gov.au/>. 
The BEACH survey data 2007–08 and 2008–09 were collected by the Family Medicine 
Research Centre of the University of Sydney in collaboration with the Australian Institute of 
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Health and Welfare. Data for the Disease Expenditure Database were derived from data 
from the NHMD, NPHED and Health Expenditure Database as well as survey based data. 
Timeliness 
The reference period for this data set is 2008–09. The Disease Expenditure Database can only 
be updated once the NHMD, NPHED, NHCDC and Health Expenditure Databases have all 
been updated for the relevant financial year, which is currently a minimum of 15 months 
after the end of the financial year. 
The AIHW first published 2008–09 data from the Disease Expenditure Database in Australia’s 
health 2012 in June 2012. 
Accessibility 
The AIHW provides a variety of products that draw upon the Disease Expenditure Database 
2008–09. Published products currently available on the AIHW website include: 
• Australia’s health 2012  
• Dementia in Australia  
• Incontinence in Australia: prevalence, experience and cost 
Users can request data not available online or in reports via the Expenditure and Economics 
Unit on (02) 6244 1119 or via email to <expenditure@aihw.gov.au>. Requests that take longer 
than half an hour to compile are charged for on a cost-recovery basis. 
Interpretability 
Supporting information on the quality and use of the Disease Expenditure Database are 
published in Health system expenditure on disease and injury in Australia, 2004–05 (technical 
notes), available in hard copy or on the AIHW website.  
Most important to note is that the Disease Expenditure Database estimates: 
• are a conservative estimate based on around 70% of total recurrent health expenditure  
• are only one measure of the size of the disease burden on the community (that is, the 
‘size of the problem’)  
• are not the same as loss of health due to disease  
• should not be regarded as how much would be saved if a specific disease or all diseases 
were prevented 
• are not an estimate of the total economic impact of diseases in the Australian 
community. This is because the estimates do not include costs that are not accrued by the 
health system, such as travel costs of patients, costs associated with the social and 
economic burden on carers and family, and owing to lost quality and quantity of life. 
Relevance 
Disease expenditure estimates provide a broad picture of the use of health system resources 
classified by disease group, as well as a reference source for planners and researchers 
interested in costs and use patterns for particular disease groups.  
The Disease Expenditure Database contains a conservative estimate based on around 70% of 
total recurrent health expenditure. 
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It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that was not able to be allocated by disease includes: capital expenditure, 
non-admitted patient hospital services, over-the-counter drugs, other health practitioner 
services (except optometry), community health services expenditure (except community 
mental health), expenditure on public health programs (except cancer screening programs), 
health administration, health aids and appliances, and patient transport (ambulance). 
Readers need to bear in mind that cost-of-illness data only provide estimates of the impact of 
a disease on health system expenditures. The estimates of the cost of treating and/or 
preventing a disease cannot be used to indicate the loss of health due to that disease.  
Care should be taken not to interpret expenditure associated with disease treatment as 
simply an estimate of the savings that would result from prevention of disease. Conversion 
of the opportunity cost—or the benefits forgone—of resources being devoted to disease 
treatment into expenditure savings involves a number of additional considerations. See, for 
example, AIHW: Mathers & Penm 1998. 
Accuracy 
Apart from hospital admitted patient services data, the method for estimating disease 
expenditure is generally a ‘top–down’ approach where total expenditure across the health 
system is estimated and then allocated to the relevant conditions. Although this method 
yields consistency, good coverage, and totals that add up to known expenditures, it is not as 
sensitive or accurate for any specific disease as a detailed ‘bottom–up’ analysis of actual costs 
incurred by patients with that disease. In most cases, a bottom up analysis is not possible due 
to a lack of available data. 
Both out-of-hospital medical services and prescription pharmaceuticals expenditure 
estimates draw upon proportions derived from BEACH surveys relating to 2007 to 2009. In 
each BEACH survey, the vocationally registered GPs and all general practice registrars who 
claimed a minimum of 375 general practice A1 Medicare items in the most recently available 
3 months make up the population from which a sample is drawn (Britt et al. 2009). GPs are 
randomly selected from this population and approached for participation in the survey. Each 
BEACH survey includes a sample of 1,000 recognised practising GPs across the country 
(about a 6% of all recognised practising GPs) completing details for 100 consecutive GP 
encounters. Each BEACH survey contains details of about 100,000 encounters between GPs 
and patients (about a 0.1% sample of all general practice encounters) (Britt et al. 2009). For 
further information regarding data collection methods in BEACH surveys, refer to the 
General practice activity in Australia 2008–09 report (Britt et al. 2009). In light of these sampling 
methods used, time series comparisons of expenditure estimates for out-of-hospital medical 
services and prescription pharmaceuticals need to be treated with caution. Refer to the data 
quality statements for the NHMD, NPHED and the Health Expenditure Database for further 
information on the accuracy of the data within these databases. 
Coherence 
To ensure consistency between the Disease Expenditure Database and associated burden of 
disease projects, the disease groups used in the 2008–09 disease expenditure estimates were 
based on the 176 diseases that were published in the Australian burden of disease studies 
(AIHW: Mathers et al. 1999; Begg et al. 2007). Extra categories were added to provide a more 
comprehensive list of diseases and the two categories of ‘Symptoms, signs and ill-defined 
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conditions’ and ‘Other contact with health services’ were included to cover some health 
service expenditures that cannot be allocated by disease.  
The methodologies used to estimate expenditures for admitted patient hospital services have 
remained unchanged between 2004–05 and 2008–09. Hence, time series comparisons for 
admitted patient hospital services are possible.  
While the methodologies used to estimate expenditures for out-of-hospital medical services 
and prescription pharmaceuticals have also remained unchanged between 2004–05 and 
2008–09, the use of the BEACH survey-based data in the methodologies has meant that time 
series comparisons for these areas of expenditure should be made with caution. 
Comparisons over time for optometrical and dental services, community mental health 
services and public health cancer screening can be made with more confidence. 
Implementation date 
6 February 2012 
Source and reference attributes 
AIHW (Australian Institute of Health and Welfare): Mathers & Penm 1998. Disease costing 
methodology used in the Disease Costs and Impact Study 1993–94. Cat. no. HWE 7. 
Canberra: AIHW. 
AIHW: Mathers, C et al. 1999. The burden of disease and injury in Australia. Cat. no. PHW 
17. Canberra: AIHW. 
Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez AD 2007. The burden of disease and 
injury in Australia 2003. AIHW Cat. no. PHE 82. Canberra: AIHW. 
Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y et al. 2009. General practice 
activity in Australia 2008-09. General practice series no. 25. Cat. no. GEP 25. Canberra: 
AIHW. 
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Appendix B 
Statistical tables  
 
Table B1: Average expenditure per encounter with the health system, by health-care  
sector by sex, Australia, 2008–09, ($) 
Health-care sector(a) Males Females Persons 
Hospital admitted patient services(b) 8,197 6,828 7,567 
Out-of-hospital medical expenses 41 43 42 
Blood glucose lowering medications 46 48 47 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis 
Source: Disease Expenditure Database, AIHW. 
 
 
 
Table B2: Diabetes expenditure by health-care sector by sex, Australia, 2008–09  
 Males  Females  Persons 
Health-care sector(a) $ (million) %  $ (million) %  $ (million) % 
Hospital admitted patient services(b) 378 58.5  268 41.5  647 100.0 
Out-of-hospital medical expenses 207 57.1  155 42.9  362 100.0 
Blood glucose lowering medications 260 52.2  238 47.8  498 100.0 
Total allocated expenditure(c) 845 56.1  662 43.9  1,507 100.0 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
(c)  Values may not sum to the total due to rounding. 
Source: Disease Expenditure Database, AIHW. 
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Table B3: Diabetes expenditure by health-care sector, constant prices, Australia, 2000–01, 
2004–05 and 2008–09, ($ million) 
Health-care sector 2000–01 2004–05 2008–09 
Diabetes(a)    
Hospital admitted patient services(b) 300 429 647 
Out-of-hospital medical expenses 269 327 362 
Blood glucose lowering medications 242 278 498 
Total allocated expenditure on diabetes(c) 811 1,034 1,507 
All diseases 40,699 49,757 65,129 
Diabetes expenditure as a proportion of expenditure on all diseases (%) 2.0 2.1 2.3 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
(c)  Values may not sum to the total due to rounding. 
Source: Disease Expenditure Database, AIHW. 
 
 
 
Table B4: Diabetes expenditure by health-care sector by diabetes type, Australia, 2008–09 
 Type 1  Type 2  Other/Unspecified   Total 
Health-care sector(a) $ (million) %  $ (million) %  $ (million) %  $ (million) % 
Hospital admitted patient services(b) 96 14.8  544 84.1  7 1.1  647 100.0 
Out-of-hospital medical expenses 23 6.3  175 48.4  164 45.4  362 100.0 
Blood glucose lowering medications 96 19.2  198 39.8  204 41.0  498 100.0 
Total allocated expenditure(c) 214 14.2  918 60.9  376 24.9  1,507 100.0 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
(c)  Values may not sum to the total due to rounding. 
Source: Disease Expenditure Database, AIHW. 
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Table B5: Diabetes services by health-care sector by diabetes type, Australia, 2008–09 
 Type 1  Type 2  Other/Unspecified  Total 
Health-care sector(a) 
Number of 
services %  
Number of 
services %  
Number of 
services %  
Number of 
services % 
Hospital admitted 
patient services(b) 16,300 19.1  68,200 79.8  900 1.0  85,500 100.0 
Out-of-hospital 
medical expenses 421,500 4.8  4,166,500 47.9  4,105,200 47.2  8,693,200 100.0 
Blood glucose 
lowering medications 579,500 5.5  5,575,400 52.6  4,443,600 41.9  10,598,500 100.0 
Total services(c) 1,017,300 5.2  9,810,100 50.6  8,549,700 44.1  19,377,100 100.0 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
(c)  Values may not sum to the total due to rounding. 
Source: Disease Expenditure Database, AIHW. 
 
 
 
Table B6: Diabetes expenditure by health-care sector by age, Australia, 2008–09 
 
0 to 24 
years  
25 to 44 
years  
45 to 64 
years  
65 to 84 
years  85+ years  Total 
Health-care 
sector(a) 
$ 
million %  
$ 
million %  
$ 
million %  
$ 
million %  
$ 
million %  
$ 
million % 
Hospital 
admitted patient 
services(b) 30 4.7  56 8.7  197 30.5  311 48.1  52 8.1  647 100.0 
Out-of-hospital 
medical 
expenses 4 1.0  26 7.1  154 42.5  168 46.3  11 3.0  362 100.0 
Blood glucose 
lowering 
medications 19 3.9  50 10.0  211 42.4  204 40.9  14 2.8  498 100.0 
Total allocated 
expenditure(c) 53 3.5  132 8.7  563 37.3  683 45.3  77 5.1  1,507 100.0 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
(c)  Values may not sum to the total due to rounding. 
Source: Disease Expenditure Database, AIHW. 
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Table B7: Diabetes services by health-care sector by age, 2008–09 
  0 to 24 years   25 to 44 years 
  
45 to 64 years 
  
65 to 84 years 85+ years 
 
Total 
Health-care 
sector(a) Services %   Services %   Services %   Services % Services % 
 
Services % 
Hospital admitted 
patient services(b) 6,697 7.8  7,142 8.4 
 
21,108 24.7 
 
44,360 51.9 6,155 7.2 
 
85,462 100.0 
Out-of-hospital 
medical expenses 65,286 0.8  523,143 6.0 
 
3,556,721 40.9 
 
4,279,530 49.2 268,547 3.1 
 
8,693,227 100.0 
Blood glucose 
lowering 
medications 
164,524 1.6  602,468 5.7 
 
4,406,610 41.6 
 
5,051,989 47.7 372,830 3.5 
 
10,598,421 100.0 
Total services(c) 236,507 1.2   1,132,753 5.8   7,984,438 41.2   9,375,880 48.4 647,532 3.3 
 
19,377,110 100.0 
(a)  Includes ICD-10 categories E10, E11, E13, E14. Does not include E09. 
(b)  Expenditure for hospital admitted patient services for diabetes includes only cases where diabetes was the principal diagnosis. 
(c)  Values may not sum to the total due to rounding. 
Source: Disease Expenditure Database, AIHW. 
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Glossary 
additional diagnosis: An additional diagnosis is a condition or complaint that coexists with 
the principal diagnosis or arises during an episode of (hospital) care. 
admitted patient: A patient who undergoes a hospital’s formal admission process to receive 
treatment and/or care. This treatment, and/or care, is provided over a period of time and 
can occur in hospital and/or in the person’s home (for hospital-in-the-home patients). 
Bettering the Evaluation and Care of Health (BEACH): An ongoing national survey of 
general practitioners in Australia, conducted by the Australian General Practice Statistics 
and Classification Centre, at the University of Sydney. It involves a random sample of about 
1,000 general practitioners per year, each of whom records the details of 100 consecutive 
patient encounters. 
constant prices: Constant price expenditure adjusts current prices for the effects of inflation; 
that is, it aims to remove the effects of inflation.  
diabetes (diabetes mellitus): A chronic condition in which the body cannot use its main 
energy source, the sugar glucose. This is due to either the pancreas not producing enough of 
the hormone, insulin, or the body being unable to effectively use the insulin produced, or 
both. 
Diabetes Pilot Program: An Australian Government program to review and refine the 
Diabetes Medication Assistance Service—an ongoing cycle of assessment, management and 
review of patients with Type 2 diabetes.  
Disease Expenditure Database: The AIHW Disease Expenditure Database contains 
estimates of expenditure by disease category, age group and sex for admitted patient 
hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services and public health cancer 
screening. 
gestational diabetes mellitus: Diabetes mellitus which begins or is first recognised during 
pregnancy. Women with gestational diabetes, and their offspring, are at greater risk of 
developing Type 2 diabetes later in life. Gestational diabetes increases the risk of perinatal 
morbidity and mortality. 
Juvenile Diabetes Research Foundation (JDRF): A charitable organisation that supports 
research into Type 1 diabetes, directed at finding a cure for the disease. 
Medicare Benefits Schedule (MBS): A Department of Health and Ageing list which is part 
of the Medicare Benefits Scheme, the aim of which is to provide an entitlement to benefits for 
medical and hospital services for all Australian residents. 
National Diabetes Services Scheme (NDSS): The NDSS is an Australian Government 
initiative that subsidises the supply of insulin syringes, needles, insulin infusion pump 
consumables and diagnostic reagents (blood and urine testing strips) to people with diabetes 
who are registered with the scheme. Registration is free. The scheme was established in 1987 
and is administered by Diabetes Australia. 
Other types of diabetes: There are a number of conditions or syndromes that come under 
this category. They may result from genetic defects, infection or disease, or they may be 
drug- or chemical-induced diabetes, such as steroid-induced diabetes.  
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National Diabetes Strategy: Endorsed by Australian Health Ministers and recognising 
diabetes as a National Health Priority Area in Australia, the National Diabetes Strategy aims 
to contribute to the improvement of the general level of Australia’s health by reducing the 
personal and public burden of diabetes in Australia through the implementation of a number 
of strategic initiatives.  
Pharmaceutical Benefits Scheme (PBS): An Australian Government-funded scheme that 
subsidises the cost of a wide range of pharmaceutical drugs and covers all Australians to 
help them afford standard medications. 
principal diagnosis: The diagnosis established after study to be chiefly responsible for 
occasioning the patient’s episode of care in hospital. 
Repatriation Pharmaceutical Benefits Scheme (RPBS): This scheme provides assistance to 
eligible veterans (with recognised war, or service-related disabilities) and their dependants 
for both pharmaceuticals listed on the PBS and a supplementary repatriation list, at the same 
cost as patients entitled to the concessional payment under the PBS. 
separation: An episode of care in a hospital. This can refer to either the total stay or a portion 
of the total stay which ends in change of the type of care.  
Type 1 diabetes: A form of diabetes marked by a complete lack of insulin and needing 
insulin replacement for survival. This form of diabetes mostly arises in childhood or in 
young adults, but it can occur at any age.  
Type 2 diabetes: The most common form of diabetes, which is characterised by reduced 
insulin secretion or less effective insulin action. Management options may include lifestyle 
modification, such as changes in diet along with increased exercise and weight loss, and 
medications such as oral glucose-lowering drugs and insulin. 
Unspecified diabetes: Includes those cases where the diabetes type has not been recorded.  
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Between 2000–01 and 2008–09, health-care expenditure 
allocated to diabetes increased by 86% from $811 million 
to $1,507 million.
The health-care sector where the largest increase 
took place was hospital admitted patients for which 
expenditure more than doubled in this period. Type 2 
diabetes accounted for 60% of diabetes expenditure in 
2008–09.
